🚨Today in @cp-cancercell.bsky.social: 50,000 tumor genomes via MSK-IMPACT. We map which HLA alleles are highest yield for antigen discovery—and define when HLA LOH constrains targetability. A framework for scaling TCR therapies. @mskcancercenter.bsky.social authors.elsevier.com/sd/article/S...

Register for the 2026 Spring Scientific! This program will feature in-depth explorations and discussions of recent scientific breakthroughs, cutting-edge technologies, and the newest clinical studies. View the full list of faculty and sessions: www.sitcancer.org/spring-scientific-schedule-2026

Latest preprint from the team: micropolymorphisms in HLAs tune peptide conformational ensembles, altering structural adaptability & contributing to TCR specificity. Even if static structures & pep affinites are the same, closely related HLAs may not be. #immunosky www.biorxiv.org/content/10.6...

HLA micropolymorphisms confine neoantigen conformational adaptability and guide T cell receptor selectivity

T cell receptor (TCR) restriction by highly polymorphic major histocompatibility complex (MHC) proteins is a foundation of cellular immunity. Although the effects of MHC polymorphisms on peptide bindi...

biorxiv.org

🚨This week in @natcomms.nature.com: We resolve an enduring enigma in T cell biology—how TCR binding to p/HLA triggers intracellular signaling. CryoEM in native environment reveals a 'jack-in-the-box' mechanism! Collab btw @rockefeller.edu @mskcancercenter.bsky.social rdcu.be/eUPPl

The resting and ligand-bound states of the membrane-embedded human T-cell receptor–CD3 complex

Nature Communications - The T-cell receptor (TCR) activation mechanism has remained uncertain. Here, the authors present molecular structures for the apo and ligand-bound human TCR–CD3...

rdcu.be

Excited to announce a new paper in ‪@aacrjournals.bsky.social‬ with Junwei Shi and Tony Daniyan. We perform screens of GAPs and GEFs in AML and discover a hematopoietic-specific GAP (ARHGAP45) required in a variety of hematologic malignancies: aacrjournals.org/cancerdiscov...

📢New Article published at Nature Cancer! ✒️By Christopher Klebanoff and colleagues 'CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit' 🔗 www.nature.com/articles/s43...

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit - Nature Cancer

Klebanoff and colleagues report that survival and persistence of CAR-T and CAR-NK cells are regulated by a FAS ligand–FAS autoregulatory circuit, showing that disabling FAS signaling enhances their an...

nature.com

MSK’s @klebanofflab.bsky.social and team found that FAS ligand, which hampers #CAR-T and #CAR-NK therapies, is actually produced by immune cells themselves.

Cellular Immunotherapies Carry Seeds of Self-Destruction but Can Be Rescued With Genetic Engineering

Read about a new discovery that could lead to more powerful cell-based therapies for cancer.

mskcc.org

Complete tumor eradication with cell therapies depends on persistence of donor CAR-cells in the patient @klebanofflab.bsky.social show that deletion of Fas on donor CAR-T/CAR-NK improves persistence in FasL-dependent (host NK & T) manner @natcancer.nature.com www.nature.com/articles/s43...

🚨Today, in #NatureCancer, we show that #CAR-T cells and #CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS enhances CAR potency against liquid and solid cancers. rdcu.be/exjEy. @mskcancercenter.bsky.social @parkerici.bsky.social

CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit

Nature Cancer - Klebanoff and colleagues report that survival and persistence of CAR-T and CAR-NK cells are regulated by a FAS ligand–FAS autoregulatory circuit, showing that disabling FAS...

rdcu.be

MSK physician-scientist Dr. Christopher Klebanoff talked about all things #neoantigens for the Novel Classes of Human Cancer Rejection Antigens session this morning at #AACR25.

This is part of a long-standing collaboration with Rob Bradley’s lab ‪@fredhutch.bsky.social‬ and with amazing TCR discovery expertise from Chris Klebanoff’s lab @klebanofflab.bsky.social @mskcancercenter.bsky.social‬‬. Also incredible help from Jeff Molldrem @mdanderson.bsky.social‬‬‬‬‬